Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pristiq for Reward Processing in MDD
NCT02859103Phase 4Completed
- Sponsor
- Unity Health Toronto
- Start
- Jun 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of desvenlafaxine in major depressive disorder (MDD), sponsored by Unity Health Toronto. Started Jun 2017; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02859103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859103.